{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:15:11Z","timestamp":1790007311427,"version":"4.0.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis, Spain"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The reimbursement of erenumab in Spain and other European countries is currently restricted because of the cost of this novel therapy to patients with migraine who have experienced previous failures to traditional preventive treatments. However, this reimbursement policy should be preferably based on cost-effectiveness studies, among other criteria. This study performed a cost-effectiveness analysis of erenumab versus topiramate for the prophylactic treatment of episodic migraine (EM) and versus placebo for chronic migraine (CM).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A Markov model with a 10-year time horizon, from the perspective of the Spanish National Healthcare System, was constructed based on data from responder and non-responder patients. A responder was defined as having a minimum 50% reduction in the number of monthly migraine days (MMD). A hypothetical cohort of patients with EM with one or more prior preventive treatment failures and patients with CM with more than two treatment failures was considered. The effectiveness score was measured as an incremental cost per quality-adjusted life year (QALY) gained and cost per migraine day (MD) avoided. Data from clinical outcomes and patient characteristics were obtained from erenumab clinical trials (NCT02066415, STRIVE, ARISE, LIBERTY and HER-MES). Deterministic and probabilistic sensitivity analyses were performed to validate the robustness of the model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After a 10-year follow-up, the estimated QALYs were 5.88 and 6.11 for patients with EM treated with topiramate and erenumab, respectively. Erenumab showed an incremental cost per patient of \u20ac4,420 vs topiramate. For CM patients, erenumab resulted in 0.756 QALYs gained vs placebo; and an incremental cost of \u20ac1,814. Patients treated with erenumab achieved reductions in MD for both EM and CM (172 and 568 MDs, respectively). The incremental cost per QALY gained with erenumab was below the Spanish threshold of \u20ac30,000\/QALY for both health and societal perspectives (EM \u20ac19,122\/QALY and CM \u20ac2,398\/QALY).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Erenumab is cost-effective versus topiramate as a preventive treatment for EM and versus placebo for patients with CM from the perspective of the Spanish National Health System.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-024-01747-w","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T13:01:49Z","timestamp":1710507709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Patricia","family":"Pozo-Rosich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Poveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Irimia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"issue":"5","key":"1747_CR1","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","volume":"19","author":"M Linde","year":"2012","unstructured":"Linde M, Gustavsson A, Stovner LJ et al (2012) The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 19(5):703\u2013711. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03612.x","journal-title":"Eur J Neurol"},{"issue":"4","key":"1747_CR2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","volume":"37","author":"RC Burch","year":"2019","unstructured":"Burch RC, Buse DC, Lipton RB (2019) Migraine: epidemiology, burden and comorbidity. Neurol Clin 37(4):631\u2013649. https:\/\/doi.org\/10.1016\/j.ncl.2019.06.001","journal-title":"Neurol Clin"},{"issue":"1","key":"1747_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s10194-018-0946-z","volume":"19","author":"P Martelletti","year":"2018","unstructured":"Martelletti P, Schwedt TJ, Lanteri-Minet M et al (2018) My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain 19(1):115. https:\/\/doi.org\/10.1186\/s10194-018-0946-z","journal-title":"J Headache Pain"},{"issue":"11","key":"1747_CR4","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"LJ Stovner","year":"2018","unstructured":"Stovner LJ, Nichols E, Steiner TJ et al (2018) Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17(11):954\u2013976. https:\/\/doi.org\/10.1016\/S1474-4422(18)30322-3","journal-title":"Lancet Neurol"},{"issue":"9","key":"1747_CR5","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.1007\/s10072-022-06178-6","volume":"43","author":"MF Rossi","year":"2022","unstructured":"Rossi MF, Tumminello A, Marconi M et al (2022) Sex and gender differences in migraines: a narrative review. Neurol Sci 43(9):5729\u20135734. https:\/\/doi.org\/10.1007\/s10072-022-06178-6","journal-title":"Neurol Sci"},{"issue":"1","key":"1747_CR6","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1186\/s12889-019-7461-2","volume":"19","author":"\u00c1 Lubl\u00f3y","year":"2019","unstructured":"Lubl\u00f3y \u00c1 (2019) Economic burden of migraine in Latvia and Lithuania: direct and indirect costs. BMC Public Health 19(1):1242. https:\/\/doi.org\/10.1186\/s12889-019-7461-2","journal-title":"BMC Public Health"},{"issue":"4","key":"1747_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10194-008-0051-9","volume":"9","author":"FS Mennini","year":"2008","unstructured":"Mennini FS, Gitto L, Martelletti P (2008) Improving care through health economics analyses: cost of illness and headache. J Headache Pain 9(4):199\u2013206. https:\/\/doi.org\/10.1007\/s10194-008-0051-9","journal-title":"J Headache Pain"},{"issue":"8","key":"1747_CR8","doi-asserted-by":"publisher","first-page":"e105471","DOI":"10.1371\/journal.pone.0105471","volume":"9","author":"O Par\u00e9s-Badell","year":"2014","unstructured":"Par\u00e9s-Badell O, Barbaglia G, Jerinic P, Gustavsson A, Salvador-Carulla L, Alonso J (2014) Cost of Disorders of the Brain in Spain. Foffani G, ed. PLoS One 9(8):e105471. https:\/\/doi.org\/10.1371\/journal.pone.0105471","journal-title":"PLoS One"},{"issue":"12","key":"1747_CR9","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1111\/ene.14431","volume":"27","author":"P Irimia","year":"2020","unstructured":"Irimia P, Garrido-Cumbrera M, Santos-Lasaosa S et al (2020) Estimating the savings associated with a migraine-free life: results from the Spanish Atlas. Eur J Neurol 27(12):2616\u20132624. https:\/\/doi.org\/10.1111\/ene.14431","journal-title":"Eur J Neurol"},{"issue":"1","key":"1747_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1468-1331.2011.03590.x","volume":"19","author":"J Olesen","year":"2012","unstructured":"Olesen J, Gustavsson A, Svensson M, Wittchen HU, J\u00f6nsson B (2012) The economic cost of brain disorders in Europe. Eur J Neurol 19(1):155\u2013162. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03590.x","journal-title":"Eur J Neurol"},{"issue":"3","key":"1747_CR11","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1007\/s00415-021-10715-2","volume":"269","author":"E Caronna","year":"2022","unstructured":"Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (2022) Epidemiology, work and economic impact of migraine in a large hospital cohort: time to raise awareness and promote sustainability. J Neurol 269(3):1456\u20131462. https:\/\/doi.org\/10.1007\/s00415-021-10715-2","journal-title":"J Neurol"},{"key":"1747_CR12","doi-asserted-by":"publisher","unstructured":"D\u00edaz-Insa S, Navarro-Zornoza M, S\u00e1nchez-de la Rosa R, Guerrero AL. Caracterizaci\u00f3n del manejo del paciente con migra\u00f1a en Atenci\u00f3n Primaria en Espa\u00f1a. An\u00e1lisis de los resultados del proyecto europeo My-LIFE anamnesis. Neurolog\u00eda. Published online January 2022. https:\/\/doi.org\/10.1016\/j.nrl.2021.10.012","DOI":"10.1016\/j.nrl.2021.10.012"},{"key":"1747_CR13","unstructured":"Manual de Pr\u00e1ctica Cl\u00ednica en Cefaleas. Recomendaciones diagn\u00f3sticoterap\u00e9uticas de la Sociedad Espa\u00f1ola de Neurolog\u00eda en 2020. \u00a9 2020, Sociedad Espa\u00f1ola de Neurolog\u00eda ISBN: 978-84-18420-19-1."},{"issue":"5","key":"1747_CR14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis. Cephalalgia 37(5):470\u2013485. https:\/\/doi.org\/10.1177\/0333102416678382","journal-title":"Cephalalgia"},{"issue":"1","key":"1747_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10194-022-01448-2","volume":"23","author":"P Irimia","year":"2022","unstructured":"Irimia P, Garc\u00eda-Azor\u00edn D, N\u00fa\u00f1ez M et al (2022) Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study. J Headache Pain 23(1):78. https:\/\/doi.org\/10.1186\/s10194-022-01448-2","journal-title":"J Headache Pain"},{"key":"1747_CR16","unstructured":"Ficha T\u00e9cnica VYEPTI 100 mg concentrado para soluci\u00f3n para perfusi\u00f3n. 2023. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1211599001\/FT_1211599001.html"},{"key":"1747_CR17","unstructured":"Ficha T\u00e9cnica AJOVY 225 mg soluci\u00f3n inyectable en jeringa o pluma precargada. 2019. Agencia Espa\u00f1ola de\u00a0Medicamentos y Productos Sanitarios. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1191358001\/FT_1191358001.html"},{"key":"1747_CR18","unstructured":"Ficha T\u00e9cnica Emgality 120 mg soluci\u00f3n inyectable en pluma precargada. 2018. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1181330001\/FT_1181330001.html#9"},{"key":"1747_CR19","unstructured":"Sanidad M. BIFIMED: Buscador de la Informaci\u00f3n sobre la situaci\u00f3n de financiaci\u00f3n de los medicamentos: erenumab. Published online 2022."},{"issue":"1","key":"1747_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013 2022 update. J Headache Pain 23(1):67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x","journal-title":"J Headache Pain"},{"key":"1747_CR21","unstructured":"National Headache Foundation. National Headache Foundation Position Statement on the Treatment of Migraine and Access to Care. NHF. 2022. https:\/\/headaches.org\/national-headache-foundation-position-statement-on-the-treatment-of-migraine\/#:~:text=In%20keeping%20with%20our%20vision,patient%20at%20the%20right%20time"},{"key":"1747_CR22","doi-asserted-by":"crossref","unstructured":"Basu A, Maciejewski ML (2019) Choosing a Time Horizon in Cost and Cost-effectiveness Analyses. In: Livingston EH, Lewis RJ, eds. JAMA Guide to Statistics and Methods. McGraw-Hill Education. https:\/\/jamaevidence.mhmedical.com\/content.aspx?bookid=2742\u00a7ionid=233568307.","DOI":"10.1001\/jama.2019.1153"},{"key":"1747_CR23","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW (2015) Methods for the economic evaluation of health care programmes. 4th ed. Oxford University Press, Oxford"},{"issue":"1","key":"1747_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S10194-023-01682-2\/FIGURES\/4","volume":"24","author":"JB Hong","year":"2023","unstructured":"Hong JB, Lange KS, Fitzek M et al (2023) Impact of a reimbursement policy change on treatment with erenumab in migraine \u2013 a real-world experience from Germany. J Headache Pain 24(1):1\u201310. https:\/\/doi.org\/10.1186\/S10194-023-01682-2\/FIGURES\/4","journal-title":"J Headache Pain"},{"key":"1747_CR25","unstructured":"Gil-Gouveia R, Dolezil D, Paemeleire K, et al (2022) Sustained benefit of monthly erenumab versus daily oral preventives in episodic migraine patients from the APPRAISE study. 8th Congress of the European Academy of Neurology - Europe, Vienna, pp S11.001"},{"issue":"2","key":"1747_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","volume":"42","author":"U Reuter","year":"2022","unstructured":"Reuter U, Ehrlich M, Gendolla A et al (2022) Erenumab versus topiramate for the prevention of migraine \u2013 a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia 42(2):108\u2013118. https:\/\/doi.org\/10.1177\/03331024211053571","journal-title":"Cephalalgia"},{"issue":"1","key":"1747_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s10194-022-01492-y","volume":"23","author":"S Khanal","year":"2022","unstructured":"Khanal S, Underwood M, Naghdi S et al (2022) A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine. J Headache Pain 23(1):122. https:\/\/doi.org\/10.1186\/s10194-022-01492-y","journal-title":"J Headache Pain"},{"issue":"22","key":"1747_CR28","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y et al (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377(22):2123\u20132132. https:\/\/doi.org\/10.1056\/NEJMoa1705848","journal-title":"N Engl J Med"},{"issue":"10161","key":"1747_CR29","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. The Lancet 392(10161):2280\u20132287. https:\/\/doi.org\/10.1016\/S0140-6736(18)32534-0","journal-title":"The Lancet"},{"issue":"6","key":"1747_CR30","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL et al (2018) ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38(6):1026\u20131037. https:\/\/doi.org\/10.1177\/0333102418759786","journal-title":"Cephalalgia"},{"issue":"6","key":"1747_CR31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425\u2013434. https:\/\/doi.org\/10.1016\/S1474-4422(17)30083-2","journal-title":"Lancet Neurol"},{"issue":"2","key":"1747_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.gaceta.2019.06.007","volume":"34","author":"JA Sacrist\u00e1n","year":"2020","unstructured":"Sacrist\u00e1n JA, Oliva J, Campillo-Artero C et al (2020) \u00bfQu\u00e9 es una intervenci\u00f3n sanitaria eficiente en Espa\u00f1a en 2020? Gac Sanit 34(2):189\u2013193. https:\/\/doi.org\/10.1016\/j.gaceta.2019.06.007","journal-title":"Gac Sanit"},{"issue":"1","key":"1747_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F et al (2022) Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health 25(1):3\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.11.1351","journal-title":"Value Health"},{"issue":"5","key":"1747_CR34","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10198-010-0244-4","volume":"11","author":"J L\u00f3pez-Bastida","year":"2010","unstructured":"L\u00f3pez-Bastida J, Oliva J, Anto\u00f1anzas F et al (2010) Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ 11(5):513\u2013520. https:\/\/doi.org\/10.1007\/s10198-010-0244-4","journal-title":"Eur J Health Econ"},{"key":"1747_CR35","unstructured":"Instituto Nacional de Estad\u00edstica (INE)\u00a0(2020) Tablas de mortalidad por a\u00f1o, sexo, edad y funciones. Resultados nacionales, por comunidades aut\u00f3nomas y provincias. Instituto Nacional de Estad\u00edstica,\u00a0Madrid"},{"issue":"1","key":"1747_CR36","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 20(1):22\u201333. https:\/\/doi.org\/10.18553\/jmcp.2014.20.1.22","journal-title":"J Manag Care Pharm"},{"issue":"5","key":"1747_CR37","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, Goadsby PJ, Reuter U et al (2021) Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28(5):1716\u20131725. https:\/\/doi.org\/10.1111\/ene.14715","journal-title":"Eur J Neurol"},{"issue":"4","key":"1747_CR38","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3111\/13696990701616992","volume":"10","author":"IM Turner","year":"2007","unstructured":"Turner IM, Newman SM, Entin EJ, Agrillo T (2007) Prophylactic treatment of migraine with botulinum toxin type A: a pharmacoeconomic analysis in a community setting. J Med Econ 10(4):355\u2013366. https:\/\/doi.org\/10.3111\/13696990701616992","journal-title":"J Med Econ"},{"key":"1747_CR39","unstructured":"General Pharmaceutical Council of Spain. Drug database. Bot plus. General Pharmaceutical Council of Spain. Published 2022. https:\/\/botplusweb.portalfarma.com\/. Accessed 23 Sept 2022"},{"key":"1747_CR40","unstructured":"Bolet\u00edn Oficial del Estado. Real Decreto-ley 8\/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducci\u00f3n del d\u00e9ficit p\u00fablico. Published online 210AD:126:45070"},{"key":"1747_CR41","unstructured":"Bolet\u00edn Oficial de Arag\u00f3n, n\u00fam. 165. 29\/08\/2017. ORDEN SAN\/1221\/2017, de 21 de julio, por la que se establecen los precios y tarifas m\u00e1ximas aplicables en la prestaci\u00f3n de servicios sanitarios con medios ajenos al Sistema de Salud de Arag\u00f3n. Gobierno de Arag\u00f3n. 2017. https:\/\/www.boa.aragon.es\/cgi-bin\/EBOA\/BRSCGI?CMD=VEROBJ&MLKOB=977342223030"},{"key":"1747_CR42","unstructured":"Bolet\u00edn Oficial de Arag\u00f3n. ORDEN SAN\/401\/2020, de 11 de mayo, por la que se modifica el anexo de la Orden SAN\/1221\/2017, de 21 de julio, por la que se establecen los precios y tarifas m\u00e1ximas aplicables en la prestaci\u00f3n de servicios sanitarios con medios ajenos al Sistema de Salud. Published online 2020:11343\u201311388"},{"key":"1747_CR43","unstructured":"Bolet\u00edn Oficial de Canarias. Resoluci\u00f3n de 29 de Marzo de 2017, Del Director, Por La Que Se Modifica La Cuant\u00eda de Los Precios P\u00fablicos de Servicios Sanitarios Previstos En El Decreto 81\/2009, de 16 de Junio, Por El Que Se Establecen Los Precios P\u00fablicos de Los Servicios Sanitarios p.; 2017. Gobierno de Canarias. https:\/\/www.gobiernodecanarias.org\/boc\/2017\/067\/002.html"},{"key":"1747_CR44","first-page":"1","volume":"8134","author":"G de Catalunya","year":"2020","unstructured":"de Catalunya G (2020) ORDRE SLT\/63\/2020, de 8 de mar\u00e7, per la qual s\u2019aproven els preus p\u00fablics de Servei Catal\u00e0 de la Salut. Diari Oficial de la Generalitat de Catalunya 8134:1\u2013173","journal-title":"Diari Oficial de la Generalitat de Catalunya"},{"key":"1747_CR45","unstructured":"Junta de Castilla y Le\u00f3n. Decreto 25\/2010, de 17 de junio, sobre precios p\u00fablicos por actos asistenciales y servicios sanitarios prestados por la Gerencia Regional de Salud. Bolet\u00edn Oficial de Castilla y Le\u00f3n. Published online 2013"},{"key":"1747_CR46","unstructured":"Bolet\u00edn Oficial de Canarias. ORDEN de 11 de enero de 2022, por la que se modifica la cuant\u00eda de los precios p\u00fablicos previstos en el Anexo II del Decreto 81\/2009, de 16 de junio, que establece los precios p\u00fablicos de los servicios sanitarios prestados por el Servicio Canario de la Sa. Published online 2022:3777-3780"},{"key":"1747_CR47","unstructured":"Bolet\u00edn oficial de la regi\u00f3n de Murcia. Orden de 12 de abril de 2022 de la Consejer\u00eda de Econom\u00eda, Hacienda y Administraci\u00f3n Digital, por la que se publican las tarifas de las tasas y precios p\u00fablicos aplicables en el a\u00f1o 2022. Published online 2022:12400-12528"},{"key":"1747_CR48","unstructured":"Osakidetza. Acuerdo de 13 de diciembre de 2021, del consejo de administraci\u00f3n del ente p\u00fablico osakidetza, por el que se aprueban las tarifas por prestaci\u00f3n de servicios sanitarios y docentes a terceros obligados al pago durante el ejercicio 2022. Published online 2021"},{"key":"1747_CR49","unstructured":"Diario Oficial de Extremadura. RESOLUCI\u00d3N de 19 de enero de 2022, de la Vicepresidenta Primera y Consejera, por la que se publican las tarifas actualizadas de las tasas y precios p\u00fablicos de la Comunidad Aut\u00f3noma de Extremadura en virtud de lo dispuesto en la Ley de Presupuestos Genera. Published online 2022:4634-4859"},{"key":"1747_CR50","unstructured":"La Rioja. Orden 17\/2014, de 16 de noviembre de 2014, de la Consejer\u00eda de Administraci\u00f3n P\u00fablica y Hacienda por la que se establece y regula el precio p\u00fablico por los servicios sanitarios prestados a particulares en los centros del Servicio Riojano de Salud. Published online 2014:24921-24955"},{"key":"1747_CR51","unstructured":"Bolet\u00edn Oficial de la Junta de Andaluc\u00eda. Orden de 8 de mayo de 2018, por la que se modifica la Orden de 14 de octubre de 2005, por la que se fijan los precios p\u00fablicos de los servicios sanitarios prestados por centros dependientes del Sistema Sanitario P. 2018. Junta de Andaluc\u00eda. https:\/\/www.juntadeandalucia.es\/boja\/2018\/92\/1"},{"key":"1747_CR52","volume-title":"DeCreto 194\/2019, de 31 de octubre, de segunda modificaci\u00f3n del Decreto 87\/2009, de 29 de julio, por el que se establecen los precios p\u00fablicos a aplicar por el Servicio de Salud del Principado de Asturias por la prestaci\u00f3n de servicios sanitarios","author":"P de Asturias","year":"2019","unstructured":"de Asturias P (2019) DeCreto 194\/2019, de 31 de octubre, de segunda modificaci\u00f3n del Decreto 87\/2009, de 29 de julio, por el que se establecen los precios p\u00fablicos a aplicar por el Servicio de Salud del Principado de Asturias por la prestaci\u00f3n de servicios sanitarios. Published online, Bolet\u00edn oficial del Principado de Asturias"},{"key":"1747_CR53","unstructured":"Comunidad Foral de Navarra. RESOLUCI\u00d3N 1564\/2018, de 20 de diciembre, del Director Gerente del Servicio Navarro de Salud-Osasunbidea, por la que se establecen las tarifas por los servicios prestados por el Servicio Navarro de Salud-Osasunbidea. Published online 2018:495\u2013526"},{"key":"1747_CR54","volume-title":"ORDEN 727\/2017, de 7 de Agosto, Del Consejero de Sanidad, Por La Que Se Fijan Los Precios P\u00fablicos Por La Prestaci\u00f3n de Los Servicios y Actividades de Naturaleza Sanitaria de La Red de Centros de La Comunidad de Madrid","author":"Bolet\u00edn oficial de Madrid","year":"2017","unstructured":"Bolet\u00edn oficial de Madrid (2017) ORDEN 727\/2017, de 7 de Agosto, Del Consejero de Sanidad, Por La Que Se Fijan Los Precios P\u00fablicos Por La Prestaci\u00f3n de Los Servicios y Actividades de Naturaleza Sanitaria de La Red de Centros de La Comunidad de Madrid"},{"key":"1747_CR55","unstructured":"Generalitat Valenciana. LEY 7\/2021, de 29 de diciembre, de la Generalitat, de medidas fiscales, de gesti\u00f3n administrativa y financiera y de organizaci\u00f3n de la Generalitat 2022. Diari Oficial de la Generalitat Valenciana. Published online 2021"},{"key":"1747_CR56","unstructured":"Conseller\u00eda de sanidade. DECRETO 56\/2014, do 30 de abril, polo que se establecen as tarifas dos servizos sanitarios prestados nos centros dependentes do Servizo Galego de Sa\u00fade e nas fundaci\u00f3ns p\u00fablicas sanitarias. Diario Oficial de Galicia. Published online 2014:22788\u201322825"},{"key":"1747_CR57","unstructured":"Servicio de Salud de Castilla-La Mancha (Sescam). Resoluci\u00f3n de 09\/11\/2020, de la Direcci\u00f3n-Gerencia, que modifica la Resoluci\u00f3n de 15\/11\/2017, sobre las condiciones econ\u00f3micas aplicables a la prestaci\u00f3n de determinados servicios de asistencia sanitaria a trav\u00e9s de medios ajenos, en el \u00e1mbito de gesti\u00f3n . Diario Oficial de Castilla-La Mancha. Published online 2020:16870\u201316875"},{"key":"1747_CR58","unstructured":"Ministerio de Sanidad. Registro de Actividad de Atenci\u00f3n Especializada (RAE-CMBD) 2020. Published online 2022"},{"key":"1747_CR59","unstructured":"Instituto Nacional de Estad\u00edstica (INE). \u00cdndice de Precios al Consumo (IPC). INE. https:\/\/www.ine.es\/prensa\/ipc_tabla.htm"},{"issue":"Supplement 1","key":"1747_CR60","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1212\/WNL.56.suppl_1.S29","volume":"56","author":"J Edmeads","year":"2001","unstructured":"Edmeads J, Lainez JM, Brandes JL, Schoenen J, Freitag F (2001) Potential of the Migraine Disability Assessment (MIDAS) Questionnaire as a public health initiative and in clinical practice. Neurology 56(Supplement 1):S29\u2013S34. https:\/\/doi.org\/10.1212\/WNL.56.suppl_1.S29","journal-title":"Neurology"},{"issue":"1","key":"1747_CR61","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s10194-020-01162-x","volume":"21","author":"A Hansson-Hedblom","year":"2020","unstructured":"Hansson-Hedblom A, Axelsson I, Jacobson L, Tedroff J, Borgstr\u00f6m F (2020) Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway. J Headache Pain 21(1):99. https:\/\/doi.org\/10.1186\/s10194-020-01162-x","journal-title":"J Headache Pain"},{"key":"1747_CR62","unstructured":"Instituto Nacional de Estad\u00edstica (INE). Encuesta trimestral de coste salarial. Costes laborales por trabajador. Datos ajustados de estacionalidad y calendario. 3 trimetre de 2022. INE. Published online 2022"},{"key":"1747_CR63","unstructured":"Instituto Nacional de Estad\u00edstica (INE). Encuesta de Poblaci\u00f3n Activa (EPA). Tasa de paro del 3 trimestre de 2022. INE. Published online 2022"},{"issue":"4","key":"1747_CR64","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2165\/00019053-200422040-00002","volume":"22","author":"M Prasad","year":"2004","unstructured":"Prasad M, Wahlqvist P, Shikiar R, Shih YCT (2004) A review of self-report instruments measuring health-related work productivity. Pharmacoeconomics 22(4):225\u2013244. https:\/\/doi.org\/10.2165\/00019053-200422040-00002","journal-title":"Pharmacoeconomics"},{"key":"1747_CR65","unstructured":"Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S (2010) Applied methods of cost-effectiveness analysis in healthcare. Oxford University Press,\u00a0Oxford"},{"key":"1747_CR66","doi-asserted-by":"crossref","unstructured":"Briggs A, Claxton K, Sculpher M (2006) Decision modelling for health economic evaluation. Oxford University Press,\u00a0Oxford","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"issue":"8","key":"1747_CR67","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/hec.635","volume":"10","author":"E Fenwick","year":"2001","unstructured":"Fenwick E, Claxton K, Sculpher M (2001) Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 10(8):779\u2013787. https:\/\/doi.org\/10.1002\/hec.635","journal-title":"Health Econ"},{"issue":"10","key":"1747_CR68","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1177\/0333102418796842","volume":"38","author":"M Sussman","year":"2018","unstructured":"Sussman M, Benner J, Neumann P, Menzin J (2018) Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives. Cephalalgia 38(10):1644\u20131657. https:\/\/doi.org\/10.1177\/0333102418796842","journal-title":"Cephalalgia"},{"issue":"1","key":"1747_CR69","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12883-023-03302-7","volume":"23","author":"N Siersb\u00e6k","year":"2023","unstructured":"Siersb\u00e6k N, Kilsdal L, Jervelund C, Antic S, Bendtsen L (2023) Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine. BMC Neurol 23(1):254. https:\/\/doi.org\/10.1186\/s12883-023-03302-7","journal-title":"BMC Neurol"},{"issue":"1","key":"1747_CR70","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40120-021-00303-x","volume":"11","author":"H Autio","year":"2022","unstructured":"Autio H, Purmonen T, Kurki S et al (2022) Erenumab decreases headache-related sick leave days and health care visits: a retrospective real-world study in working patients with migraine. Neurol Ther 11(1):223\u2013235. https:\/\/doi.org\/10.1007\/s40120-021-00303-x","journal-title":"Neurol Ther"},{"key":"1747_CR71","unstructured":"Bundesausschuss G, Joint Committee F (2021) Resolution of the federal joint committee on an amendment of the pharmaceuticals directive: annex XII-benefit assessment of medicinal products with new active ingredients according to section 35a SGB V Erenumab (Reassessment Due to New Scientific Knowledge (Prophylaxis of Migraine)). https:\/\/www.g-ba.de\/downloads\/39-1464-5066\/2021-10-21_AM-RL-XII_Erenumab_D-669_EN.pdf. Accessed 18 April 2023"},{"issue":"1","key":"1747_CR72","first-page":"17","volume":"99","author":"H Ha","year":"2019","unstructured":"Ha H, Gonzalez A (2019) Migraine headache prophylaxis. Am Fam Physician 99(1):17\u201324. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30600979","journal-title":"Am Fam Physician"},{"key":"1747_CR73","unstructured":"Bajwa ZH SJ. Preventive treatment of migraine in adults. Post TW, ed UpToDate. Published online 2018. https:\/\/www.uptodate.com\/contents\/preventive-treatment-of-migraine-in-adults?search=preventivo%20de%20migra%C3%B1a&source=-search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Accessed 15 June 2018"},{"key":"1747_CR74","unstructured":"Ficha t\u00e9cnica Aimovig\u00ae 70mg, 140 mg, soluci\u00f3n inyectable en jeringa o pluma precargada. 2023. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1181293004\/FT_1181293004.html"},{"issue":"1","key":"1747_CR75","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s10194-018-0923-6","volume":"19","author":"T Schwedt","year":"2018","unstructured":"Schwedt T, Reuter U, Tepper S et al (2018) Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain 19(1):92. https:\/\/doi.org\/10.1186\/s10194-018-0923-6","journal-title":"J Headache Pain"},{"issue":"1","key":"1747_CR76","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10194-021-01335-2","volume":"22","author":"F Vandervorst","year":"2021","unstructured":"Vandervorst F, Van Deun L, Van Dycke A et al (2021) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain 22(1):128. https:\/\/doi.org\/10.1186\/s10194-021-01335-2","journal-title":"J Headache Pain"},{"issue":"6","key":"1747_CR77","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","volume":"15","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM (2012) Modeling good research practices\u2013overview: a report of the ISPOR-SMDM modeling good research practices task force\u20131. Value Health 15(6):796\u2013803. https:\/\/doi.org\/10.1016\/j.jval.2012.06.012","journal-title":"Value Health"},{"issue":"01","key":"1747_CR78","doi-asserted-by":"publisher","first-page":"8","DOI":"10.33588\/rn.7401.2021182","volume":"74","author":"A Caso Gonz\u00e1lez","year":"2022","unstructured":"Caso Gonz\u00e1lez A, Leralta Gonz\u00e1lez C, Sanz Alonso V, Iturbe Heras M, Hernando de la B\u00e1rcena I, Obaldia Ala\u00f1a C (2022) Experiencia cl\u00ednica con erenumab durante el primer a\u00f1o de tratamiento. Rev Neurol 74(01):8. https:\/\/doi.org\/10.33588\/rn.7401.2021182","journal-title":"Rev Neurol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01747-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01747-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01747-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T13:02:31Z","timestamp":1710507751000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01747-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1747"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01747-w","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]},"assertion":[{"value":"24 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PP-R has earned fees from Novartis. JLP has earned fees from Novartis. PI has earned fees from Novartis. CC works in Axentiva Solutions, a consultancy firm that works for several pharmaceutical companies. MM and JMR work for Novartis Espa\u00f1a.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}